{"disease":{"id":"multiple-myeloma-in-remission","name":"multiple myeloma in remission"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04184050","title":"Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT03428373","title":"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03650491","title":"A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Fortis Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06006741","title":"Universal CAR-T Cells Targeting Multiple Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT03687125","title":"Tinostamustine Conditioning and Autologous Stem Cell","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Mundipharma-EDO GmbH","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}